



The future of medicine lies in technology convergence – the combination of biotech, pharmaceuticals and devices in its various forms. Another term for these convergent medical technologies is BioDevice combinations which include drug-device combos, implantable drug-delivery systems, medical nanotechnology and a host of other futuristic systems. The area of convergent/combo medical technologies received exposure in a recent article in the *Economist* “Devices and their Desires” (4/12/06). You can find that article [here](#).

This is an area of enormous growth but also of great challenge. Conventional investment categories include biotech, pharma and devices and as such there is relatively little industry thought leadership in this area. On this website you will find cutting-edge content from DuraVest, its advisory boards and others that lead the way in this true “category killer” area of medical technology. Visit our [ThinkTank](#) for more information.

In addition, we feature the underlying science underlying the technologies being developed by our subsidiaries. These include [next-generation drug-eluting stents](#) (which represent the paradigm for such convergent technologies) and [bio-magnetic therapeutic devices](#).